Opinion

Video

Unmet Needs in IPF Landscape

Author(s):

Justin Oldham, MD, MS

Critical voids in the management of idiopathic pulmonary fibrosis are discussed by Justin Oldham, MD, MS.

Video content above is prompted by the following:

  • What are the current unmet needs in IPF treatment and why is it necessary to develop new pharmacotherapies for this disease?
  • What biomarkers are currently used for the diagnosis of IPF?
Related Videos
1 expert in this video
1 expert in this video
4 experts are featured in this series.
4 experts are featured in this series.
2 experts in this video
2 experts in this video
5 experts are featured in this series
5 experts are featured in this series
Related Content
Overall, there were 36 factors identified as having a prognostic impact on at least 1 clinical outcome. | Image Credit: laszlo - stock.adobe.com
May 16th 2025

Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL

AJMC Contributor
A systematic review and subsequent expert review gave comprehensive insight into prognostic factors for patients receiving treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
managed care cast logo
December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
FDA headquarters | Image Credit: Tada Images - stock.adobe.com
May 16th 2025

Retifanlimab Becomes First FDA-Approved Frontline Treatment for Advanced Anal Cancer

Brooke McCormick
The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported by data from the POD1UM-303/InterAACT2 and POD1UM-202 trials.
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
Pulmonology care team | Image credit: Peakstock – stock.adobe.com
May 16th 2025

Spotlighting Innovations in Pulmonary Care at ATS 2025

Hayden E. Klein
Late-breaking findings on pulmonology, critical care, and sleep medicine will be presented at the American Thoracic Society (ATS) 2025 International Conference.
Transplant-free survival from the time of right-heart catheterization was also significantly longer in the dual therapy group. | Image Credit: mi_viri - stock.adobe.com
May 15th 2025

Dual Therapy Appears to Benefit Patients With Pulmonary Fibrosis, Pulmonary Hypertension

Jared Kaltwasser
The combination of antifibrotic therapy and pulmonary vasodilator therapy improved transplant-free survival but had no significant impact on exercise capacity in pulmonary fibrosis and pulmonary hypertension.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo